Home Clinical Topics FDA approves Afrezza

FDA approves Afrezza

On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here